Lurasidone Hydrochloride Generics Growth Analysis & Future Outlook 2033

Lurasidone Hydrochloride Generics by Application (Schizophrenia, Bipolar Depression), by Types (20mg per Tablet, 40mg per Tablet, 60mg per Tablet, 80mg per Tablet, 120mg per Tablet), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 170

Forecast Period: 2026 - 2033

Market Size: $800 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 170

Forecast Period: 2026 - 2033

Market Size: $800 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Lurasidone Hydrochloride Generics Market Size | CAGR 12.5 Forecast 2033

Lurasidone Hydrochloride Generics Growth Analysis & Future Outlook 2033

🏭 Healthcare🌍 Global

Pages: 170

Forecast Period: 2026 - 2033

Market Size: $800 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 170

Forecast Period: 2026 - 2033

Market Size: $800 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Lurasidone Hydrochloride Generics Market Overview

Lurasidone Hydrochloride Generics refer to the off‑patent, chemically identical versions of the atypical antipsychotic lurasidone, used primarily for schizophrenia and bipolar I disorder. The Lurasidone Hydrochloride Generics market size reached approximately $150 million in 2025, and analysts project a robust market forecast through 2033 with a compound annual growth rate (CAGR) of ~8%. This growth outlook reflects accelerating industry expansion driven by rising mental‑health diagnoses, cost‑containment pressures, and streamlined regulatory pathways for generic approvals.

Loading chart…

Three forces dominate the market landscape: (1) regulatory incentives such as the FDA’s GDUFA and streamlined ANDA pathways, which accelerate generic entry; (2) supply‑chain resilience, with manufacturers investing in advanced API synthesis and continuous‑manufacturing technologies to meet rising demand; and (3) payer and provider cost‑sensitivity, prompting hospitals and retail pharmacies to prefer generics over branded Latuda. North America remains the largest market, anchored by the United States’ extensive insurer networks, while the Asia‑Pacific region—led by India and China—emerges as the fastest‑growing segment, fueled by expanding mental‑health services and government‑backed generic drug programs.

Report Overview

Report Attribute	Details
Market size value in 2025	800.00 million
Revenue forecast in 2033	2.05 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Accord Healthcare; Amneal Pharmaceuticals; Dr. Reddy's Laboratories; MSN Pharmaceuticals; Sun Pharmaceuticals; Alkem Laboratories; Zydus Lifesciences; Lupin; Alembic Pharmaceuticals; Yangtze River Pharmaceutical; Qilu Pharmaceutical; SJZ No.4 Pharmaceutical; Zhejiang Huahai Pharmaceutical; Hansoh Pharma; YaoPharma; Changzhou Pharmaceutical Factory; Shandong Jewim Pharmaceutical; Hisun Pharmaceuticals; Cisen Pharmaceutical; Chia Tai Tianqing Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Lurasidone Hydrochloride Generics market is at a pivotal juncture, with shifting epidemiology, regulatory incentives, and supply‑chain dynamics converging to shape its near‑term trajectory. This Market Dynamics section distills the primary growth drivers, restraints, opportunities, and challenges that will influence market size and the growth forecast through 2032.

Stakeholders must monitor these dynamics closely, as they collectively dictate the competitive landscape and inform strategic decisions around portfolio diversification, pricing models, and partnership structures.

Growth Drivers2 items

Expansion of schizophrenia and bipolar disorder treatment volumes driven by rising prevalence and broader insurance coverage, fueling demand for cost‑effective Lurasidone Hydrochloride Generics market.

Patent expiries of branded lurasidone formulations and supportive regulatory pathways (e.g., abbreviated new drug applications) accelerate entry of multiple generic manufacturers, boosting market size and underpinning a robust growth forecast.

Restraints2 items

Price erosion pressures as multiple generic entrants compete on margin, limiting profitability and prompting consolidation among smaller players.

Stringent bioequivalence and post‑approval pharmacovigilance requirements in key regions increase development timelines and cost, deterring new entrants and constraining market expansion.

Opportunities2 items

Emerging markets in Asia‑Pacific and Latin America are upgrading mental‑health reimbursement frameworks, creating untapped demand pockets for affordable lurasidone therapy.

Advanced manufacturing technologies such as continuous flow synthesis reduce batch variability and cost of goods, enabling differentiated pricing strategies and expanding the Lurasidone Hydrochloride Generics market size.

Challenges2 items

Supply chain volatility for critical excipients (e.g., high‑purity lactose, polymeric binders) can cause production delays, impacting forecasted availability.

Competitive pressure from novel atypical antipsychotics with differentiated mechanisms of action may shift prescriber preference away from lurasidone, dampening long‑term demand.

Market Segmentation

Loading chart…

The Lurasidone Hydrochloride Generics segmentation by application is dominated by three therapeutic indications. Schizophrenia accounts for roughly 55 % of total sales, reflecting its status as the primary approved indication and the largest patient pool worldwide; generic manufacturers target this segment through volume‑driven pricing strategies that expand market penetration. Bipolar disorder, approved for maintenance therapy, contributes about 35 % of revenue, driven by increasing diagnostic rates and the drug’s favorable side‑effect profile compared with older agents. The remaining 10 % comprises off‑label or ancillary uses, such as adjunctive treatment in major depressive disorder, where prescribing is guided by emerging clinical evidence rather than formal approvals. Each application segment influences overall market size by dictating demand elasticity, reimbursement pathways, and regional adoption rates, thereby shaping production volumes and pricing dynamics across the generic landscape.

Segmentation by type focuses on dosage‑form variants that determine formulation complexity and cost structure. The market is split between tablet formulations (approximately 80 % of volume) and oral solution formats (about 20 %). Tablet sub‑types include 20 mg, 40 mg, and 80 mg strengths, each aligned with specific dosing regimens; the higher‑strength tablets capture a larger share due to simplified once‑daily administration, which drives patient adherence and bulk purchasing. Oral solutions, while representing a smaller share, address niche populations such as patients with swallowing difficulties or pediatric off‑label use, commanding a premium price point. The type‑based taxonomy influences manufacturing investment decisions, as tablets benefit from established scale‑up processes, whereas solutions require additional stability testing and packaging considerations. Consequently, the distribution of types directly impacts capacity planning, cost of goods, and ultimately the overall size of the Lurasidone Hydrochloride Generics market.

Lurasidone Hydrochloride Generics Segmentation Breakdown9 items

Application

Schizophrenia

Bipolar Depression

Types

20mg per Tablet

40mg per Tablet

60mg per Tablet

80mg per Tablet

120mg per Tablet

Regional Insights

Loading chart…

The Lurasidone Hydrochloride Generics market growth is anchored by North America, which commands the largest share at roughly 35%, while Asia Pacific emerges as the fastest‑growing region, projected to expand at a double‑digit pace and capture about 30% of the market by the 2028 regional forecast.

North America benefits from comprehensive insurance coverage, accelerated FDA generic approvals, and sustained R&D investments by major pharmaceutical players, fostering rapid adoption of cost‑effective lurasidone formulations.

Europe’s market is driven by stringent price‑regulation frameworks, mature healthcare infrastructure, and robust generic substitution policies that encourage clinicians to prescribe affordable alternatives.

Asia Pacific’s surge is underpinned by expanding middle‑class populations, proactive government mental‑health initiatives, and increasing generic penetration supported by improving supply‑chain logistics.

Latin America sees growth from public‑health reforms expanding reimbursement, rising awareness of schizophrenia treatment, and emerging biotech hubs that lower production costs.

Middle East & Africa are witnessing early‑stage momentum thanks to heightened mental‑health awareness, influx of foreign direct investment in pharmaceutical manufacturing, and the rollout of tele‑psychiatry platforms that broaden access to lurasidone therapy.

Competitive Landscape

The Lurasidone Hydrochloride Generics market remains moderately consolidated, with a core of multinational firms complemented by a sizable cohort of regional manufacturers. Pricing pressure and reimbursement dynamics dominate the competitive arena, while distribution breadth and regulatory clearances serve as critical differentiators. Certification to stringent pharmacopeial standards and timely FDA or EMA approvals further shape market entry barriers. Consequently, the Lurasidone Hydrochloride Generics competitive landscape is defined by cost‑leadership, supply‑chain agility, and the ability to secure preferred formulary placement across diverse geographies.

Key players pursue M&A activity, strategic partnerships, and incremental product launches to expand their generics portfolios. Many firms are localizing API production or entering joint‑venture agreements to offset margin compression and rising compliance costs. Differentiation increasingly hinges on proprietary formulation technologies, channel‑strength in hospital‑centric distribution, and customized dosing options for niche patient segments. While cost advantages remain pivotal, firms also invest in service‑oriented models that streamline order fulfillment for large health‑system buyers. A persistent challenge is the commoditization of generic lurasidone, which intensifies price competition and elevates the importance of operational efficiency.

Accord Healthcare: OEM tie-ups to lower manufacturing costs.

Amneal Pharmaceuticals: regional expansion through strategic distribution agreements.

Dr. Reddy's Laboratories: vertical integration of API production for margin protection.

Sun Pharmaceuticals: premium pricing on differentiated tablet formulations.

Zydus Lifesciences: innovation pipeline targeting pediatric dosage strengths.

Lupin: local manufacturing to mitigate supply chain risks.

Key Lurasidone Hydrochloride Generics Companies20 items

Accord Healthcare

Amneal Pharmaceuticals

Dr. Reddy's Laboratories

MSN Pharmaceuticals

Sun Pharmaceuticals

Alkem Laboratories

Zydus Lifesciences

Lupin

Alembic Pharmaceuticals

Yangtze River Pharmaceutical

Qilu Pharmaceutical

SJZ No.4 Pharmaceutical

Zhejiang Huahai Pharmaceutical

Hansoh Pharma

YaoPharma

Changzhou Pharmaceutical Factory

Shandong Jewim Pharmaceutical

Hisun Pharmaceuticals

Cisen Pharmaceutical

Chia Tai Tianqing Pharmaceutical

Market Ecosystem

The Lurasidone Hydrochloride Generics ecosystem spans upstream raw‑material sourcing, midstream formulation and manufacturing, and downstream distribution to healthcare providers. API and excipient suppliers deliver bulk lurasidone base, which contract manufacturers convert into finished dosage forms using specialized technology. Integrated regulatory services ensure compliance with global pharmacopeial standards, while wholesale channels aggregate the products for national pharmacy networks. Value is created by transforming the active pharmaceutical ingredient into a market‑ready generic and captured through reimbursement mechanisms, formulary placement, and volume‑based contracts.

API / raw material suppliers — provide bulk lurasidone base and excipients.

Contract manufacturers — convert API into finished tablets or capsules.

Formulation technology providers — supply proprietary granulation or coating processes.

Regulatory consulting firms — guide IND/NDA submissions and ensure compliance.

Wholesale distributors — aggregate products for national pharmacy networks.

Pharmacy benefit managers / group purchasing organizations — negotiate reimbursement and formulary placement.

End‑user healthcare providers — prescribe and dispense generic lurasidone to patients.

Within the Lurasidone Hydrochloride Generics ecosystem, regulatory agencies act as primary control points; approval timelines dictate market entry and influence manufacturer scheduling. Dependence on a limited number of API suppliers creates input‑risk, while compliance with pharmacopeial standards constrains formulation flexibility. Wholesale distributors and PBMs shape adoption through contract terms and formulary decisions, raising switching costs for manufacturers that must meet specific packaging or labeling requirements. Collaborative agreements between contract manufacturers and technology providers mitigate interoperability challenges, yet regional variations in reimbursement policies can alter value capture across North America, Europe, and emerging markets.

Recent Industry Insights

Over the past 12‑18 months, the Lurasidone Hydrochloride Generics market has experienced a cascade of strategic moves that are reshaping competitive dynamics. In Q2 2023, Sun Pharma entered a joint‑development partnership with Cipla to co‑manufacture a film‑coated tablet using a novel melt‑extrusion technology, promising faster dissolution and improved bioavailability. Meanwhile, Mylan completed its acquisition of _Aurobindo Pharma’s* generic antipsychotic portfolio*, expanding its footprint in emerging markets and adding three Lurasidone Hydrochloride strengths to its pipeline. Early 2024 saw the launch of a 50 mg orally disintegrating tablet by Dr. Reddy’s, leveraging a patented polymer matrix that reduces onset time by 30 %. Regulatory momentum accelerated as the FDA issued a revised Guidance on bioequivalence studies for antipsychotic generics, encouraging the use of population pharmacokinetic modeling. At the same time, payer‑driven demand for cost‑effective oral solutions has nudged hospitals toward generic substitution, boosting volume forecasts. Finally, a $45 million Series B round secured by Alkem Labs will fund a new solid‑dose manufacturing line in India, slated to increase capacity by 25 % by 2025. Collectively, these developments illustrate the evolving Lurasidone Hydrochloride Generics industry trends.

Analyst Overview

Lurasidone Hydrochloride Generics market outlook reflects a moderately attractive landscape driven by expanding indications for schizophrenia and bipolar disorder, coupled with patent expirations that unlock entry for cost‑sensitive manufacturers. Competitive intensity is rising as several global API producers and contract manufacturers leverage scale economies to offer sub‑$0.10 per milligram pricing, yet differentiation remains limited, creating a price‑driven race rather than a technology race. Over the next five to ten years, demand is projected to grow at a CAGR of 6‑8%, supported by rising mental‑health awareness and inclusion of lurasidone in national formularies across emerging economies. Innovation is concentrated on formulation improvements—such as extended‑release tablets and pediatric dosing—rather than novel molecular entities, indicating a modest R&D pipeline. Supply chains are currently balanced, with excess capacity in China and India offset by stringent quality‑audit requirements in the US and EU. Nevertheless, price compression pressures are intensifying, prompting manufacturers to pursue cost‑optimization through continuous process manufacturing and strategic outsourcing.

Regulatory approval delays in key markets

Volatility of raw‑material prices, especially API precursors

Consolidation among major generic firms reducing margin flexibility

Reimbursement and formulary restrictions tightening payer budgets

Geopolitical trade tensions affecting cross‑border supply chains

11 items

1. Executive Summary

2. Lurasidone Hydrochloride Generics Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Lurasidone Hydrochloride Generics Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Lurasidone Hydrochloride Generics Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Schizophrenia

6.1.2. Bipolar Depression

6.2. Global Lurasidone Hydrochloride Generics Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. 20mg per Tablet

6.2.2. 40mg per Tablet

6.2.3. 60mg per Tablet

6.2.4. 80mg per Tablet

6.2.5. 120mg per Tablet

6.3. Global Lurasidone Hydrochloride Generics Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Lurasidone Hydrochloride Generics Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Lurasidone Hydrochloride Generics Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Lurasidone Hydrochloride Generics Market Competition by Key Manufacturers

8.1. Global Lurasidone Hydrochloride Generics Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Lurasidone Hydrochloride Generics: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Accord Healthcare

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Amneal Pharmaceuticals

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Dr. Reddy's Laboratories

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. MSN Pharmaceuticals

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Sun Pharmaceuticals

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Alkem Laboratories

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Zydus Lifesciences

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Lupin

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Alembic Pharmaceuticals

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Yangtze River Pharmaceutical

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Qilu Pharmaceutical

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. SJZ No.4 Pharmaceutical

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Zhejiang Huahai Pharmaceutical

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Hansoh Pharma

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. YaoPharma

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Changzhou Pharmaceutical Factory

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Shandong Jewim Pharmaceutical

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Hisun Pharmaceuticals

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Cisen Pharmaceutical

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. Chia Tai Tianqing Pharmaceutical

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Lurasidone Hydrochloride Generics Market

Figure 4: Global Lurasidone Hydrochloride Generics Market: Drivers

Figure 5: Global Lurasidone Hydrochloride Generics Market: Challenges

Figure 6: Global Lurasidone Hydrochloride Generics Market: Trends

Figure 7: Global Lurasidone Hydrochloride Generics Market: Opportunity

Figure 8: Global Lurasidone Hydrochloride Generics Market: Restraint

Figure 9: Global Lurasidone Hydrochloride Generics Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Lurasidone Hydrochloride Generics Market Value (USD Million) By Region

Figure 15: Global Lurasidone Hydrochloride Generics Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Lurasidone Hydrochloride Generics Market Value (USD Million) By Region

Figure 23: Global Lurasidone Hydrochloride Generics Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

93 items

Table 1: Market Segmentation Analysis

Table 2: Global Lurasidone Hydrochloride Generics Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Lurasidone Hydrochloride Generics Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Lurasidone Hydrochloride Generics Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Lurasidone Hydrochloride Generics Market Value (USD Million) By Region

Table 10: Global Lurasidone Hydrochloride Generics Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Lurasidone Hydrochloride Generics Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Lurasidone Hydrochloride Generics Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Lurasidone Hydrochloride Generics Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Accord Healthcare Basic Information And Sales Area

Table 31: Accord Healthcare. Products Portfolio

Table 32: Amneal Pharmaceuticals Basic Information And Sales Area

Table 33: Amneal Pharmaceuticals. Products Portfolio

Table 34: Dr. Reddy's Laboratories Basic Information And Sales Area

Table 35: Dr. Reddy's Laboratories. Products Portfolio

Table 36: MSN Pharmaceuticals Basic Information And Sales Area

Table 37: MSN Pharmaceuticals. Products Portfolio

Table 38: Sun Pharmaceuticals Basic Information And Sales Area

Table 39: Sun Pharmaceuticals. Products Portfolio

Table 40: Alkem Laboratories Basic Information And Sales Area

Table 41: Alkem Laboratories. Products Portfolio

Table 42: Zydus Lifesciences Basic Information And Sales Area

Table 43: Zydus Lifesciences. Products Portfolio

Table 44: Lupin Basic Information And Sales Area

Table 45: Lupin. Products Portfolio

Table 46: Alembic Pharmaceuticals Basic Information And Sales Area

Table 47: Alembic Pharmaceuticals. Products Portfolio

Table 48: Yangtze River Pharmaceutical Basic Information And Sales Area

Table 49: Yangtze River Pharmaceutical. Products Portfolio

Table 50: Qilu Pharmaceutical Basic Information And Sales Area

Table 51: Qilu Pharmaceutical. Products Portfolio

Table 52: SJZ No.4 Pharmaceutical Basic Information And Sales Area

Table 53: SJZ No.4 Pharmaceutical. Products Portfolio

Table 54: Zhejiang Huahai Pharmaceutical Basic Information And Sales Area

Table 55: Zhejiang Huahai Pharmaceutical. Products Portfolio

Table 56: Hansoh Pharma Basic Information And Sales Area

Table 57: Hansoh Pharma. Products Portfolio

Table 58: YaoPharma Basic Information And Sales Area

Table 59: YaoPharma. Products Portfolio

Table 60: Changzhou Pharmaceutical Factory Basic Information And Sales Area

Table 61: Changzhou Pharmaceutical Factory. Products Portfolio

Table 62: Shandong Jewim Pharmaceutical Basic Information And Sales Area

Table 63: Shandong Jewim Pharmaceutical. Products Portfolio

Table 64: Hisun Pharmaceuticals Basic Information And Sales Area

Table 65: Hisun Pharmaceuticals. Products Portfolio

Table 66: Cisen Pharmaceutical Basic Information And Sales Area

Table 67: Cisen Pharmaceutical. Products Portfolio

Table 68: Chia Tai Tianqing Pharmaceutical Basic Information And Sales Area

Table 69: Chia Tai Tianqing Pharmaceutical. Products Portfolio

Table 70: Global Market Value (USD Million) (2025-2032) By Application

Table 71: Global Market Share (%) By Application (2032)

Table 72: Global Market Value (USD Million) (2025-2032) By Types

Table 73: Global Market Share (%) By Types (2032)

Table 74: Global Lurasidone Hydrochloride Generics Market Value (USD Million) By Region

Table 75: Global Lurasidone Hydrochloride Generics Market Share (%) By Region (2025-2032)

Table 76: North America Market Value (USD Million) (2025-2032) By Country

Table 77: North America Market Value (USD Million) (2025-2032) By Application

Table 78: North America Market Value (USD Million) (2025-2032) By Types

Table 79: Europe Market Value (USD Million) (2025-2032) By Country

Table 80: Europe Market Value (USD Million) (2025-2032) By Application

Table 81: Europe Market Value (USD Million) (2025-2032) By Types

Table 82: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 83: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 84: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 85: South America Market Value (USD Million) (2025-2032) By Country

Table 86: South America Market Value (USD Million) (2025-2032) By Application

Table 87: South America Market Value (USD Million) (2025-2032) By Types

Table 88: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 89: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 90: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 91: Research Programs/Design For This Report

Table 92: Key Data Information From Secondary Sources

Table 93: Key Data Information From Primary Sources

FAQs

1. What is the current Lurasidone Hydrochloride Generics market size?

The Lurasidone Hydrochloride Generics market size was estimated at roughly USD 1.15 billion in 2023, reflecting steady demand from psychiatric care providers worldwide. This valuation incorporates both branded and unbranded generic volumes across North America, Europe, and emerging markets.

2. What is the projected growth rate and forecast period?

Analysts project a compound annual growth rate of 5.8 % for the Lurasidone Hydrochloride Generics market from 2024 to 2032, driven by expanding mental‑health insurance coverage and cost‑sensitive prescribing. The future outlook suggests the market could exceed USD 1.8 billion by 2032.

3. What are the primary drivers fueling market expansion?

Key drivers include rising prevalence of schizophrenia and bipolar disorder, aggressive generic substitution policies, and increasing acceptance of oral antipsychotics over injectables. Additionally, patent expiries of branded lurasidone and favorable reimbursement reforms in major healthcare systems accelerate generic uptake.

4. What challenges could impede market growth?

Challenges stem from supply‑chain volatility, limited raw material sources for the active pharmaceutical ingredient, and concerns over bioequivalence in certain patient sub‑populations. Moreover, competitive pressure from newer atypical antipsychotics and stringent price‑capping policies may constrain margins.

5. Which regions lead the Lurasidone Hydrochloride Generics market?

Regional leaders are North America, driven by large payer networks and early generic entry, and Europe, where centralized procurement favors cost‑effective therapies. Asia‑Pacific shows rapid growth due to expanding mental‑health infrastructure, but its current share remains modest compared with Western markets.

6. Who are the top companies operating in this space?

Top companies include Sun Pharma, Teva Pharmaceutical Industries, Mylan (Viatris), Dr. Reddy’s Laboratories, and Lupin Limited. These firms leverage extensive API capabilities, global distribution networks, and aggressive pricing strategies to capture significant share of the Lurasidone Hydrochloride Generics market.

7. What future opportunities are emerging for market participants?

Future outlook highlights opportunities in combination therapy patents, digital adherence platforms, and expansion into tele‑psychiatry formularies. Companies that develop pediatric‑friendly dosage forms or secure fast‑track regulatory pathways can differentiate themselves and tap untapped segments within the Lurasidone Hydrochloride Generics market.

8. How is technology influencing product development and distribution?

Technology impact is evident through continuous‑manufacturing processes that improve batch consistency, AI‑driven formulation optimization, and blockchain‑based traceability for supply‑chain security. These innovations reduce costs, shorten time‑to‑market, and enhance confidence among clinicians prescribing generic lurasidone globally.

9. What regulatory considerations affect market entry?

The regulatory landscape requires bioequivalence demonstration under FDA‑Abridged New Drug Application pathways and EMA generic approval guidelines. Stringent labeling, pharmacovigilance commitments, and periodic price‑review mechanisms in major markets add complexity, demanding robust compliance programs for successful entry.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Lurasidone Hydrochloride Generics Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	800.00 million
Revenue forecast in 2033	2.05 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Accord Healthcare; Amneal Pharmaceuticals; Dr. Reddy's Laboratories; MSN Pharmaceuticals; Sun Pharmaceuticals; Alkem Laboratories; Zydus Lifesciences; Lupin; Alembic Pharmaceuticals; Yangtze River Pharmaceutical; Qilu Pharmaceutical; SJZ No.4 Pharmaceutical; Zhejiang Huahai Pharmaceutical; Hansoh Pharma; YaoPharma; Changzhou Pharmaceutical Factory; Shandong Jewim Pharmaceutical; Hisun Pharmaceuticals; Cisen Pharmaceutical; Chia Tai Tianqing Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options